ODAC Asks Sandoz If Biosimilar Price Is Right
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee member wants to know if approval of filgrastim would lead to lower prices; Sandoz responds that price may be at parity, but cost to patients and payers would be lower.
You may also be interested in...
Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
US FDA estimates mandating naloxone co-prescriptions could dramatically increase spending to more than total estimated cost of opioid crisis itself; joint advisory committee to consider options to increase naloxone availability.
Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim
Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.